Compare ATXG & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATXG | PRPH |
|---|---|---|
| Founded | 2014 | 1989 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 6.0M |
| IPO Year | N/A | 1997 |
| Metric | ATXG | PRPH |
|---|---|---|
| Price | $0.46 | $0.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 54.1K | ★ 21.6M |
| Earning Date | 11-14-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,141,952.00 | ★ $5,055,000.00 |
| Revenue This Year | N/A | $221.82 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.36 | $0.08 |
| 52 Week High | $1.86 | $0.93 |
| Indicator | ATXG | PRPH |
|---|---|---|
| Relative Strength Index (RSI) | 42.73 | 24.11 |
| Support Level | $0.46 | $0.11 |
| Resistance Level | $0.50 | $0.12 |
| Average True Range (ATR) | 0.03 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 21.77 | 8.37 |
Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.